ArticleCancer cell2013
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.
Article in Cancer cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02963090 (A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer), which is not on this map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer
Who cites it
95 citing papers in PubMed.
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8Oncoimmunology · 2026Article
- Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases.Oncoimmunology · 2025Article
- Mimicry in the Bite: Shared Sequences BetweenProteomes · 2025Article
- Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).International journal of oncology · 2025Review
- SUMOylation-related genes define prognostic subtypes in stomach adenocarcinoma: integrating single-cell analysis and machine learning analyses.Frontiers in immunology · 2025Article
- Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies.Blood neoplasia · 2024Article
- A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice.Nature communications · 2024Article
- CD4Science immunology · 2024Article
- One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.Cancer research communications · 2024Article
- A systematic safety pipeline for selection of T-cell receptors to enter clinical use.NPJ vaccines · 2023Article
- The landscape of T cell antigens for cancer immunotherapy.Nature cancer · 2023Review
- Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer.Life (Basel, Switzerland) · 2023Review
- IFN-γ-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis.Science advances · 2022Article
- ADAM12 is an independent predictor of poor prognosis in liver cancer.Scientific reports · 2022Article
- CD8Nature reviews. Immunology · 2022Review
- Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.Biomedicines · 2022Review
- Neo-Splicetopes in Tumor Therapy: A Lost Case?Frontiers in immunology · 2022Review
- Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.Journal for immunotherapy of cancer · 2021Article
- Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer.Nature cancer · 2021Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.